This difference did not reach statistical significance, suggesting that monotherapy based upon IL-1β blockade was inefficacious in the rapid-onset RIP-GP mouse model, paralleling the recent clinical trial experience ( 17 ).
← all excerpts
Combination therapy with an anti-IL-1β antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model.
1
—
—